Ischemic Stroke in the Neurocritical Care Unit

  • Steven K. FeskeEmail author
Part of the Current Clinical Neurology book series (CCNEU)


Ischemic stroke is the most common diagnosis in the neurointensive care unit (NCCU). Patients with acute ischemic stroke may require rapid interventions for time-sensitive pharmacologic thrombolysis or endovascular thrombectomy. Many such patients will benefit from close monitoring with optimization of hemodynamic variables and observation for complications. In addition, these patients may suffer complications of acute stroke, including expansion of infarction, hemorrhagic transformation, and malignant cerebral edema. The NCCU provides an environment for physiologic monitoring by intensivists and specialized nurses and for rapid early intervention allowing us to optimize outcomes from acute ischemic stroke. This chapter addresses the role of the neurointensivist in the care of patients with acute ischemic stroke.


Ischemic stroke Cerebral infarction Thrombolysis Alteplase Endovascular thrombectomy Cardio-embolism Malignant cerebral edema 


  1. 1.
    Jauch EC, Saver JL, Adams HP, American Heart Association Stroke Council on Cardiovascular Nursing CoPVD, and Council on Clinical Cardiology, et al. Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2013;44:870–947.PubMedCrossRefGoogle Scholar
  2. 2.
    Demaerschalk BM, Kleindorfer DO, Adeoye OM, American Heart Association Stroke Council and Council on Epidemiology and Prevention, et al. Scientific rationale for the inclusion and exclusion criteria for intravenous alteplase in acute ischemic stroke: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2016;47:581–641.PubMedCrossRefGoogle Scholar
  3. 3.
    Powers WJ, Rabinstein AA, Ackerson T, et al. Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2018;2018:49.Google Scholar
  4. 4.
    The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med. 1995;333:1581–7.CrossRefGoogle Scholar
  5. 5.
    Hacke W, Kaste M, Fieschi C, ECASS Study Group, et al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke: the European Cooperative Acute Stroke Study (ECASS). JAMA. 1995;274:1017–25.PubMedCrossRefGoogle Scholar
  6. 6.
    Hacke W, Kaste M, Fieschi C, et al. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Lancet. 1998;352:1245–51.PubMedCrossRefGoogle Scholar
  7. 7.
    Hacke W, Donnan G, Fieschi C, Kaste M, von Kummer R, Broderick JP, Brott T, Frankel M, Grotta JC, Haley EC Jr, Kwiatkowski T, Levine SR, Lewandowski C, Lu M, Lyden P, Marler JR, Patel S, Tilley BC, Albers G, Bluhmki E, Wilhelm M, Hamilton S, The ATLANTIS, ECASS, and NINDS rt-PA Study Group Investigators. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet. 2004;363:768–74.PubMedCrossRefGoogle Scholar
  8. 8.
    Clark WM. Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS Study: a randomized controlled trial. JAMA. 1999;282:2019–26.PubMedCrossRefGoogle Scholar
  9. 9.
    Clark WM, Albers GW, Madden KP, Hamilton S. The rtPA (Alteplase) 0- to 6-hour acute stroke trial, part A (A0276g): results of a double-blind, placebo-controlled, multicenter study. Stroke. 2000;31:811–6.PubMedCrossRefGoogle Scholar
  10. 10.
    Davis SM, Donnan GA, Parsons MW, EPITHET Investigators, et al. Effects of alteplase beyond 3 h after stroke in the Echoplanar Imaging Thrombolysis Evaluation Trial (EPITHET): a placebo-controlled randomised trial. Lancet Neurol. 2008;7:299–309.PubMedCrossRefGoogle Scholar
  11. 11.
    Hacke W, Kaste M, Bluhmki E, EPITHET Investigators, et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med. 2008;359:1317–29.PubMedCrossRefGoogle Scholar
  12. 12.
    Albers GW, Bates VE, Clark WM, Bell R, Verro P, Hamilton SA. Intravenous tissue-type plasminogen activator for treatment of acute stroke: the Standard Treatment with Atleplase to Reverse Stroke (STARS) Study. JAMA. 2000;283:1145–50.PubMedCrossRefGoogle Scholar
  13. 13.
    Hill MD, Buchan AM. Thrombolysis for acute ischemic stroke: results of the Canadian Alteplase for Stroke Effectiveness Study. CMAJ. 2005;172:1307–12.PubMedPubMedCentralCrossRefGoogle Scholar
  14. 14.
    Wahlgren N, Ahmed N, Dávalos A, et al. Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study. Lancet. 2007;369:275–82.PubMedCrossRefGoogle Scholar
  15. 15.
    The IST-3 Collaborative Group. The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trial. Lancet. 2012;379(9834):2352–63.PubMedCentralCrossRefPubMedGoogle Scholar
  16. 16.
    Parsons M, Spratt N, Bivard A, et al. A randomized trial of tenecteplase versus alteplase for acute ischemic stroke. N Engl J Med. 2012;366:1099–107.PubMedCrossRefGoogle Scholar
  17. 17.
    Logallo N, Kvistad CE, Nacu A, et al. The Norwegian tenecteplase stroke trial (NOR-TEST): randomised controlled trial of tenecteplase vs. alteplase in acute ischaemic stroke. BMC Neurol. 2014;14:106.PubMedPubMedCentralCrossRefGoogle Scholar
  18. 18.
    Huang X, Cheripelli BK, Lloyd SM, et al. Alteplase veraus teneteplase for thrombolysis after ischaemic stroke (ATTEST): a phase 2, randomised, open-label, blinded endpoint study. Lancet Neurol. 2015;14:368–76.PubMedCrossRefGoogle Scholar
  19. 19.
    Logallo N, Novotny V, Assmus J, et al. Tenecteplase versus alteplase for management of acute ischaemic stroke (NOR-TEST): a phase 3, randomised, open-label, blinded endpoint trial. Lancet Neurol. 2017;16:781–8.PubMedCrossRefGoogle Scholar
  20. 20.
    Anderson CS. NOR-TEST-ing tenecteplase in acute ischaemic stroke. Lancet Neurol. 2017;16:762–3.PubMedCrossRefGoogle Scholar
  21. 21.
    Matosevic B, Knoflach M, Werner P, et al. Fibrinogen degradation coagulopathy and bleeding complications after stroke thrombolysis. Neurology. 2013;80:1216–24.PubMedCrossRefGoogle Scholar
  22. 22.
    Hacke W, Kaste M, Bluhmki E, et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med. 2008;359:1317–29.PubMedCrossRefGoogle Scholar
  23. 23.
    del Zoppo GJ, Higashida RT, Furlan AJ, Pessin MS, Rowley HA, Gent M. PROACT: a phase II randomized trial of recombinant pro-urokinase by direct arterial delivery in acute middle cerebral artery stroke. Stroke. 1998;29:4–11.PubMedCrossRefGoogle Scholar
  24. 24.
    Broderick JP, Palesch YY, Demchuk AM, et al. Endovascular therapy after intravenous t-PA versus t-PA alone for stroke. N Engl J Med. 2013;368:893–903.PubMedPubMedCentralCrossRefGoogle Scholar
  25. 25.
    Kidwell CS, Jahan R, Gornbein J, et al. A trial of imaging selection and endovascular treatment for ischemic stroke. N Engl J Med. 2013;368:914–23.PubMedPubMedCentralCrossRefGoogle Scholar
  26. 26.
    Ciccone A, Valvassori L, Nichelatti M, et al. Endovascular treatment for acute ischemic stroke. N Engl J Med. 2013;368:904–13.PubMedPubMedCentralCrossRefGoogle Scholar
  27. 27.
    Berkhemer OA, Fransen PS, Beumer D, et al. A randomized trial of intraarterial treatment for acute ischemic stroke. N Engl J Med. 2015;372:11–20.PubMedCrossRefGoogle Scholar
  28. 28.
    Goyal M, Demchuk AM, Menon BK, et al. Randomized assessment of rapid endovascular treatment of ischemic stroke. N Engl J Med. 2015;372:1019–30.PubMedCrossRefGoogle Scholar
  29. 29.
    Campbell BC, Mitchell PJ, Kleinig TJ, et al. Endovascular therapy for ischemic stroke with perfusion-imaging selection. N Engl J Med. 2015;372:1009–18.PubMedCrossRefGoogle Scholar
  30. 30.
    Saver JL, Goyal M, Bonafe A, et al. Stent-retriever thrombectomy after intravenous t-PA vs. t-PA alone in stroke. N Engl J Med. 2015;372:2285–95.PubMedCrossRefGoogle Scholar
  31. 31.
    Jovin TG, Chamorro A, Cobo E, et al. Thrombectomy within 8 hours after symptom onset in ischemic stroke. N Engl J Med. 2015;372:2296–306.PubMedCrossRefGoogle Scholar
  32. 32.
    Bracard S, Ducrocq X, Mas JL, et al. Mechanical thrombectomy after intravenous alteplase versus alteplase alone after stroke (THRACE): a randomised controlled trial. Lancet Neurol. 2016;15:1138–47.PubMedCrossRefGoogle Scholar
  33. 33.
    Muir KW, Ford GA, Messow CM, et al. Endovascular therapy for acute ischaemic stroke: the Pragmatic Ischaemic Stroke Thrombectomy Evaluation (PISTE) randomised, controlled trial. J Neurol Neurosurg Psychiatry. 2017;88:38–44.PubMedCrossRefGoogle Scholar
  34. 34.
    Nogueira RG, Jadhav AP, Haussen DC, et al. Thrombectomy 6 to 24 hours after stroke with a mismatch between deficit and infarct. N Engl J Med. 2018;378:11–21.PubMedCrossRefGoogle Scholar
  35. 35.
    Albers GW, Marks MP, Kemp S, et al. Thrombectomy for stroke at 6 to 16 hours with selection by perfusion imaging. N Engl J Med. 2018;378:708–18.PubMedPubMedCentralCrossRefGoogle Scholar
  36. 36.
    Nikoubashman O, Reich A, Gindullis M, et al. Clinical significance of post-interventional cerebral hyperdensities after endovascular mechanical thrombectomy in acute ischaemic stroke. Neuroradiology. 2014;56:41–50.PubMedCrossRefGoogle Scholar
  37. 37.
    Parrilla G, Garcia-Villalba B, Espinosa de Rueda M, et al. Hemorrhage/contrast staining areas after mechanical intra-arterial thrombectomy in acute ischemic stroke: imaging findings and clinical significance. AJNR Am J Neuroradiol. 2012;33(9):1791–6. Scholar
  38. 38.
    Simard JM, Chen M, Tarasov KV, et al. Newly expressed SUR1-regulated NC(Ca-ATP) channel mediates cerebral edema after ischemic stroke. Nat Med. 2006;12:433–40.PubMedPubMedCentralCrossRefGoogle Scholar
  39. 39.
    Simard JM, Yurovsky V, Tsymbalyuk N, Melnichenko L, Ivanova S, Gerzanich V. Protective effect of delayed treatment with low-dose glibenclamide in three models of ischemic stroke. Stroke. 2009;40:604–9.PubMedCrossRefPubMedCentralGoogle Scholar
  40. 40.
    Sheth KN, Taylor Kimberly W, Elm JJ, et al. Exploratory analysis of glyburide as a novel therapy for preventing brain swelling. Neurocrit Care. 2014;21:43–51.PubMedPubMedCentralCrossRefGoogle Scholar
  41. 41.
    Jüttler E, Schwab S, Schmiedek P, et al. Decompressive surgery for the treatment of malignant infarction of the middle cerebral artery (DESTINY): a randomized, controlled trial. Stroke. 2007;38:2518–25.PubMedCrossRefGoogle Scholar
  42. 42.
    Vahedi K, Hofmeijer J, Juettler E, et al. Early decompressive surgery in malignant infarction of the middle cerebral artery: a pooled analysis of three randomised controlled trials. Lancet Neurol. 2007;6:215–22.PubMedCrossRefGoogle Scholar
  43. 43.
    Hofmeijer J, Kappelle LJ, Algra A, et al. Surgical decompression for space-occupying cerebral infarction (the hemicraniectomy after middle cerebral artery infarction with life-threatening edema trial [HAMLET]): a multicenre, open, randomised trial. Lancet Neurol. 2009;8:326–33.PubMedCrossRefGoogle Scholar
  44. 44.
    Vahedi K, Vicaut E, Mateo J, et al. Sequential-design, multicenter, randomized, controlled trial of early decompressive craniectomy in malignant middle cerebral artery infarction (DECIMAL trial). Stroke. 2007;38:2506–17.PubMedCrossRefGoogle Scholar
  45. 45.
    Juttler E, Unterberg A, Woitzik J, et al. Hemicraniectomy in older patients with extensive middle-cerebral-artery stroke. N Engl J Med. 2014;370:1091–100.PubMedCrossRefGoogle Scholar
  46. 46.
    Agarwalla PK, Stapleton CJ, Ogilvy CS. Craniectomy in acute ischemic stroke. Neurosurgery. 2014;74(Suppl 1):S151–62.PubMedCrossRefGoogle Scholar
  47. 47.
    Kim MJ, Park SK, Song J, et al. Preventive suboccipital decompressive craniectomy for cerebellar infarction: a retrospective-matched case-control study. Stroke. 2016;47:2565–73.PubMedCrossRefGoogle Scholar
  48. 48.
    Pfefferkorn T, Eppinger U, Linn J, et al. Long-term outcome after suboccipital decompressive craniectomy for malignant cerebellar infarction. Stroke. 2009;40:3045–50.PubMedCrossRefGoogle Scholar
  49. 49.
    Ayling OGS, Alotaibi NM, Wang JZ, et al. Suboccipital decompressive craniectomy for cerebellar infarction: a systematic review and meta-analysis. World Neurosurg. 2018;110:450–9.. e455PubMedCrossRefGoogle Scholar
  50. 50.
    Wijdicks EF, Sheth KN, Carter BS, et al. Recommendations for the management of cerebral and cerebellar infarction with swelling: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2014;45:1222–38.PubMedCrossRefGoogle Scholar
  51. 51.
    Liman TG, Endres M. New vessels after stroke: postischemic neovascularization and regeneration. Cerebrovasc Dis. 2012;33:492–9.PubMedCrossRefGoogle Scholar
  52. 52.
    Marti HJH, Bernaudin M, Bellail A, et al. Hypoxia-induced vascular endothelial growth factor expression precedes neovascularization after cerebral ischemia. Am J Pathol. 2000;156:965–76.PubMedPubMedCentralCrossRefGoogle Scholar
  53. 53.
    Rordorf G, Koroshetz WJ, Ezzeddine MA, Segal AZ, Buonanno FS. A pilot study of drug-induced hypertension for treatment of acute stroke. Neurology. 2001;56:1210–3.PubMedCrossRefGoogle Scholar
  54. 54.
    Koenig MA, Geocadin RG, de Grouchy M, et al. Safety of induced hypertension therapy in patients with acute ischemic stroke. Neurocrit Care. 2006;4:3–7.PubMedCrossRefGoogle Scholar
  55. 55.
    The EC-IC Bypass Study Group. Failure of extracranial-intracranial arterial bypass to reduce the risk of ischemic stroke: results of an international randomized trial. N Engl J Med. 1985;313:1191–200.CrossRefGoogle Scholar
  56. 56.
    Powers WJ, Clarke WR, Grubb RL, et al. Extracranial-intracranial bypass surgery for stroke prevention in hemodynamic cerebral ischemia: the carotid occlusion surgery study randomized trial. JAMA. 2011;306:1983–92.PubMedPubMedCentralCrossRefGoogle Scholar
  57. 57.
    Derdeyn CP, Chimowitz MI, Lynn MJ, et al. Aggressive medical treatment with or without stenting in high-risk patients with intracranial artery stenosis (SAMMPRIS): the final results of a randomised trial. Lancet. 2014;383:333–41.PubMedCrossRefGoogle Scholar
  58. 58.
    Zaidat OO, Fitzsimmons BF, Woodward BK, et al. Effect of a balloon-expandable intracranial stent vs medical therapy on risk of stroke in patients with symptomatic intracranial stenosis: the VISSIT randomized clinical trial. JAMA. 2015;313:1240–8.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  1. 1.Department of NeurologyHarvard Medical SchoolBostonUSA
  2. 2.Cerebrovascular Division, Department of NeurologyBrigham and Women’s HospitalBostonUSA

Personalised recommendations